Recombinant Mouse Podocalyxin Protein, CF

Catalog #: 1556-PD Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
1556-PD-050

Recombinant Mouse Podocalyxin Protein Bioactivity

1 Image

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Mouse Podocalyxin Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE with silver staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by the ability of the immobilized protein to inhibit the adhesion of CHO Chinese hamster ovary cells transfected with P-Selectin. The ED₅₀ for this effect is 0.07-0.35 μg/mL.

Source

Mouse myeloma cell line, NS0-derived mouse Podocalyxin protein
His22-Arg402, with a C-terminal Asp and 10-His tag

Accession #

Q9R0M4

N-terminal Sequence
Analysis

His22

Predicted Molecular Mass

41 kDa (monomer)

SDS-PAGE

110-170 kDa, reducing conditions

Product Datasheets

1556-PD

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

1556-PD

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 100 μg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Mouse Podocalyxin (Catalog # 1556-PD) inhibits the adhesion of P-Selectin transfected CHO Chinese hamster ovary cells. The ED₅₀ for this effect is 0.07-0.35 μg/mL.

Reconstitution Calculator

Background: Podocalyxin

Podocalyxin (PODXL), also known as Podocalyxin-like protein 1 (PCLP-1), is a heavily glycosylated transmembrane sialoprotein in the CD34 and Endoglycan family (1). Mature mouse Podocalyxin consists of a 383 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 78 aa cytoplasmic domain (2). Within the ECD, mouse Podocalyxin shares 31% and 55% aa sequence identity with human and rat Podocalyxin, respectively. Alternative splicing of mouse Podocalyxin generates an additional isoform with a truncated intracellular region (2). Podocalyxin is expressed on glomerular and vascular endothelial cells (3, 4), neurons (5), hematopoietic, mesenchymal, and cardiac stem cells (6-9), and metastatic carcinoma and glioblastoma tumor cells (10-12). A soluble form of Podocalyxin can be released into the urine of women with pre-eclampsia (13). Podocalyxin promotes platelet activation (14), neurite outgrowth, branching, and synaptogenesis (5), homing of hematopoietic progenitor cells to the bone marrow and spleen (7), and engraftment of mesenchymal and cardiac stem cells into ischemic heart and kidney (8, 9). Its interactions with L-Selectin and E-Selectin mediate the tethering of lymphocytes and metastatic tumor cells to the vascular endothelium (4, 10, 11). Podocalyxin can be expressed as a 160-165 kDa molecule or as even larger glycoforms (3, 4, 11, 15). In humans, an approximately 200 kDa glycoform contains the carbohydrate antigen recognized by TRA-1-60 and TRA-1-81 antibodies used for the identification of undifferentiated pluripotent embryonic stem cells (15).

References

Nielsen, J.S. and K.M. McNagny (2009) J. Am. Soc. Nephrol. 20:1669.
Li, J. et al. (2001) DNA Seq. 12:407.
Kershaw, D.B. et al. (1997) J. Biol. Chem. 272:15708.
Sassetti, C. et al. (1998) J. Exp. Med. 187:1965.
Vitureira, N. et al. (2010) PLoS ONE 8:e12003.
Zhang, H. et al. (2014) Stem Cells 32:191.
Doyonnas, R. et al. (2005) Blood 105:4170.
Lee, R-H. et al. (2009) Blood 113:816.
Moscoso, I. et al. (2013) J. Tissue Eng. Regen. Med. Epub. PMID 23897803.
Dallas, M.R. et al. (2012) Am. J. Physiol. Cell Physiol. 303:C616.
Thomas, S.N. et al. (2009) Am. J. Cell Physiol. 296:C505.
Binder, Z.A. et al. (2013) PLoS ONE 8:e75945.
Wang, Y. et al. (2012) Am. J. Physiol. Renal Physiol. 302:F1084.
Alonso-Martin, S. et al. (2010) Thromb. Res. 125:e300.
Schopperle, W.M. and W.C. DeWolf (2007) Stem Cells 25:723.

Entrez Gene IDs

5420 (Human); 27205 (Mouse)

Alternate Names

GCTM; Gp200MGC138240; PCLP; PCLP1; PCLP-1; PCLPGCTM-2 antigen; PCpodocalyxin; POD XL; Podocalyxin; Podocalyxin-like protein 1; podocalyxin-like; PODXL